Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia.
Advertisement
Vemurafenib and Obinutuzumab in Hairy Cell Leukemia Patients @sloan_kettering
